Dr. Noah Berkowitz is Chief Medical Officer at Arvinas and responsible for clinical development of the company’s PROTAC protein degrader programs in oncology and neuroscience. Dr. Berkowitz has more than 20 years of experience in advancing programs through early and late stages of development, with proven ability in leading clinical development, regulatory, and medical affairs. He has led multidisciplinary teams and has extensive knowledge of clinical trial design and execution.
Prior to joining Arvinas, Dr. Berkowitz was Senior Vice President and Development Unit Head of Hematology at Bristol Myers Squibb (BMS). While at BMS, Dr. Berkowitz’s teams achieved initial or subsequent global indications for Abecma®, Breyanzi®, Reblozyl®, Onureg®, and Inrebic®, managed development life cycles for Revlimid®, Pomalyst®, and Sprycel®, and initiated and/or designed registration trials for iberdomide, mezigdomide, and alnuctamab. Before BMS, Dr. Berkowitz held roles of increasing responsibility in the areas of oncology, rare diseases, and hematology at Novartis, most recently as Vice President and Clinical Development Head for Hematology. Earlier in his career, Dr. Berkowitz was an executive at Impath (acquired by Genzyme) and founder and Chief Executive Officer of Synvista.
Dr. Berkowitz trained in Medical Oncology at the National Cancer Institute and received his M.D., Ph.D., from Columbia University.
What is Noah Berkowitz's net worth?
The estimated net worth of Noah Berkowitz is at least $1.73 million as of May 11th, 2026. Dr. Berkowitz owns 191,395 shares of Arvinas stock worth more than $1,730,019 as of May 21st. This net worth estimate does not reflect any other investments that Dr. Berkowitz may own. Learn More about Noah Berkowitz's net worth.
How do I contact Noah Berkowitz?
Has Noah Berkowitz been buying or selling shares of Arvinas?
Over the course of the past ninety days, Noah Berkowitz has sold $110,413.52 of Arvinas stock. Most recently, Noah Berkowitz sold 11,108 shares of the business's stock in a transaction on Monday, May 11th. The shares were sold at an average price of $9.94, for a transaction totalling $110,413.52. Following the completion of the sale, the insider now directly owns 191,395 shares of the company's stock, valued at $1,902,466.30. Learn More on Noah Berkowitz's trading history.
Who are Arvinas' active insiders?
Arvinas' insider roster includes Noah Berkowitz (Chief Medical Officer), Sean Cassidy (CFO), John Houston (CEO), David Loomis (CAO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Andrew Saik (Chief Financial Officer and Treasurer), Timothy Shannon (Director), Ian Taylor (Insider), and Randy Teel (CEO). Learn More on Arvinas' active insiders.
Are insiders buying or selling shares of Arvinas?
In the last year, Arvinas insiders bought shares 2 times. They purchased a total of 50,000 shares worth more than $495,100.00. In the last year, insiders at the sold shares 14 times. They sold a total of 103,617 shares worth more than $1,184,295.05. The most recent insider tranaction occured on May, 11th when CFO Andrew Saik sold 11,139 shares worth more than $110,721.66. Insiders at Arvinas own 7.3% of the company.
Learn More about insider trades at Arvinas. Information on this page was last updated on 5/11/2026.
